Company Profile
Exagen Stock Price, News & Analysis
Company overview
Business overview
Exagen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Exagen is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Exagen follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Exagen sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
XGN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Exagen’s catalysts are autoimmune diagnostics adoption, reimbursement, and whether the testing workflow keeps expanding. The market cares about recurring test utilization and coverage.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
Exagen Inc. Reports Strong Q3 2025 Results
Source: Exagen
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.